Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People who saw substantial CD4 T-cell gains during the first two years after diagnosis had better outcomes.
The Food and Drug Administration recently extended the indication for Cabenuva to include adolescents ages 12 and up.
The long-acting regimen will enable some adolescents to take their HIV treatment just six times a year.
People can now start Cabenuva injections directly without first taking cabotegravir and rilpivirine pills for a month.
The every-other-month schedule of injectable cabotegravir plus rilpivirine enables some people to take HIV treatment just six times a year.
Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.
Long-acting injectable Cabenuva works well in people with obesity.
COVID-19, HIV vaccine and cure news, and long-acting HIV treatment and prevention topped the news again this year.
The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.
This issue explores the latest choices in HIV regimens for various groups, including youth and older people.
Here are considerations for long-term survivors thinking about switching HIV treatments.
Under 30? Here’s what to consider if you’re thinking about switching HIV treatments.
Switching to a long-acting injectable was right on time for these three people living with HIV.
Injections of cabotegravir given once every two months may work even better than daily pills for HIV prevention.
People who used long-acting Cabenuva preferred the injections over their previous daily oral regimen.
Switching HIV treatments from a daily pill to a monthly injectable has given Mike Hellman more freedom outdoors.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.